Abstract

We introduce mass spectrometry proteomic research for diagnosis from a clinical perspective, with special reference to early-stage breast cancer detection. The nature of SELDI and MALDI mass spectrometric measurement is discussed. We explain how the mass spectral data arising from this technology may be viewed as a new data type. Some of the properties of the data are discussed and we show how such spectra may be interpreted. Sample preprocessing for mass spectrometry is introduced and a literature review of research in clinical proteomics is presented. Finally, we provide a detailed description of the study design on the breast cancer case-control study which is investigated in this special issue.

Submitted: January 18, 2008 · Accepted: January 23, 2008 · Published: January 25, 2008

Recommended Citation

van der Werff, Martijn P. J.; Mertens, Bart; de Noo, Mirre E.; Bladergroen, Marco R.; Dalebout, Hans C.; Tollenaar, Rob A. E. M.; and Deelder, Andre M. (2008) "Case-Control Breast Cancer Study of MALDI-TOF Proteomic Mass Spectrometry Data on Serum Samples," Statistical Applications in Genetics and Molecular Biology: Vol. 7 : Iss. 2, Article 2.
DOI: 10.2202/1544-6115.1352
Available at: http://www.bepress.com/sagmb/vol7/iss2/art2